Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its financial expectations for what it says will be a transformative year. The ...

Exact Sciences has launched its long-awaited blood test designed to detect the early stages of multiple tumors, with a plan to sell it to consumers through a telehealth program in a bid to increase ...

Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites The Cancerguard test will be delivered through Exact Sciences’ expansive commercial and operational infrastructure, ...

New evidence shows multi-biomarker class approach improved cancer detection, including in earlier stages when treatment may be more effective A new study demonstrates the ability of a multi-biomarker ...

Exact SciencesEXAS stock crashed to a three-year low Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer test. The company already developed a blood-based ...

Primary study sites Baylor Scott & White Health in Texas and Endeavor Health in Illinois aim to enroll up to 25,000 patients from diverse backgrounds, assessing the impact of MCED testing on clinical ...

Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer ...

The new, highly sensitive, tumor-informed test detects up to 200 ctDNA* variants, identifying signs of colorectal cancer (CRC) recurrence up to two years earlier than imaging—making it one of the most ...

On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...